Eli Lilly's Mounjaro (Tirzepatide), a dual GIP and GLP-1 receptor agonist, has launched in India, generating buzz as a weight ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly, which makes Zepbound and Mounjaro, reports that in a phase one clinical trial, a once daily GLP-1 pill helped lower the hemoglobin A1C, a measure of blood sugar control, in people with type ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use ...